多西他赛联合洛铂治疗晚期卵巢癌的临床疗效及对ROBO4、sB7-H4和HE4的影响  

CLINICAL EFFECT OF DOCETAXEL COMBINED WITH LOPLATIN IN THE TREATMENT OF ADVANCED OVARIAN CANCER AND ITS EFFECT ON ROBO4,SB7-H4 AND HE4

作　　者：陈芙蓉[1] 易玉兰 CHEN Furong;YI Yulan(Jingmen first people's Hospital,Jingmen 448000,China)

机构地区：[1]湖北省荆门市第一人民医院,448000 [2]黄石市中心医院

出　　处：《中国煤炭工业医学杂志》2023年第2期149-154,共6页Chinese Journal of Coal Industry Medicine

基　　金：湖北省自然科学基金项目(编号:2003ABA182)。

摘　　要：目的 探讨多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌的临床疗效及对保守单跨膜受体蛋白4(ROBO4)、可溶性B7-H4(sB7-H4)和人附睾分泌蛋白4(HE4)的影响。方法选取晚期卵巢癌患者102例,观察组给予多西他赛联合洛铂腹腔灌注治疗,对照组给予多西他赛联合卡铂静脉滴注治疗,观察两组近期疗效及不良反应等。结果 观察组近期疗效优于对照组(P<0.05),其治疗总有效率为80.00%;观察组治疗1个月后血清ROBO4为(40.32±5.11)pg/ml,高于对照组(P <0.05),而sB7-H4和HE4分别为(0.41±0.11)pg/ml和(104.40±23.32)pmol/L,低于对照组(P <0.05);观察组治疗后QLQ-C30量表躯体功能、角色功能、情绪功能社会功能及总体健康评分分别为(80.15±11.20)分、(75.50±18.80)分、(76.02±19.81)分、(71.21±11.80)分和(62.11±15.04)分,高于对照组(P<0.05);观察组中位生存时间为18个月(95%CI17.07~18.93),长于对照组(P <0.05)。结论 多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌有较好的临床疗效,患者血清ROBO4水平升高,sB7-H4和HE4水平降低。Objective To investigate the clinical effect of docetaxel combined with lotplatin intraperitoneal perfusion in the treatment of advanced ovarian cancer and its effect on the conservative single transmembrane receptor protein 4(ROBO4),soluble B7-H4(sB7-H4) and human epididymal secretory protein 4(HE4). Methods One hundred and two patients with advanced ovarian cancer were selected, according to the treatment plan, the patients were divided into observation group(n=55) and control group(n=47),the observation group was given docetaxel combined with loplatin intraperitoneal perfusion treatment, the control group was given docetaxel combined with carboplatin intravenous drip treatment, the short-term efficacy and adverse reactions of the two groups were observed. Results The short-term effect of the observation group was better than that of the control group(P<0.05),and the total effective rate was 80.00%;One month later, the serum ROBO4 of the observation group was(40.32 ± 5.11) pg/ml, which was significantly higher than that of the control group(P<0.05),while the sB7-H4 and HE4 were(0.41 ± 0.11) pg/ml and(104.40 ± 23.32) pmol/L,which were significantly lower than that of the control group(P<0.05);The scores of physical function, role function, emotional function, social function and general health of the QLQ-C30 in the observation group after treatment were(80.15±11.20),(75.50±18.80),(76.02±19.81),(71.21±11.80) and(62.11±15.04),respectively, which were significantly higher than the control group(P<0.05).The median survival time of the observation group was 18 months(95%CI 17.07~18.93),which was significantly longer than that of the control group(P<0.05);There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P<0.05). Conclusion Docetaxel combined with lotplatin intraperitoneal perfusion has a better clinical effect in the treatment of advanced ovarian cancer, can significantly increase the level of serum ROBO4 and reduce the levels of sB7-

关 键 词：多西他赛 洛铂 晚期卵巢癌 保守单跨膜受体蛋白4 可溶性B7-H4 人附睾分泌蛋白4 

分 类 号：R73[医药卫生—肿瘤]